SF Healthcare Week: The CEO of Arvinas talks protein degradation, including about the industry's first phase 3 readout that is upcoming this quarter

blonca9
Jan 15
1 min read

John Houston describes what he believes are the keys to protein degradation, and discusses the company's monotherapy and combination approach in breast cancer. Plus, Parkinson's, hematology, and more.

Recent Posts

See All

Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs

Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

SF Healthcare Week: The CEO of Arvinas talks protein degradation, including about the industry's first phase 3 readout that is upcoming this quarter

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight